Bio-Techne Corporation’s Stock Price Drops to $48.10, Experiencing a 3.75% Decrease – Is it Time to Buy?

Bio-Techne Corporation (TECH)

48.10 USD -1.88 (-3.75%) Volume: 2.74M

Bio-Techne Corporation’s stock price takes a dip, trading at 48.10 USD with a trading session decline of -3.75% and a significant YTD drop of -33.22%, amidst a trading volume of 2.74M, highlighting a challenging period for the TECH stock.

Latest developments on Bio-Techne Corporation

Today, Bio-Techne Corp’s stock price is experiencing movements following key events leading up to this moment. Leerink Partners recently adjusted the price target on Bio-Techne to $80 from $95, while maintaining an outperform rating. Additionally, Bio-Techne is set to host a conference call on May 7, 2025, to announce their third-quarter fiscal 2025 financial results. Investors are eagerly awaiting the key details that will be revealed during this call. Furthermore, Bio-Techne’s stock is expected to benefit from the expansion of their RNAscope menu, indicating potential growth and profitability in the near future.

Bio-Techne Corporation on Smartkarma

Analysts at Baptista Research have been closely following Bio-Techne Corporation, a leading life sciences company, and have published insightful research reports on Smartkarma. In one report titled “Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game!”, the analysts highlighted the company’s second-quarter results for fiscal year 2025, which showed robust growth despite some challenges. With a 9% year-over-year increase in revenue, reaching $297 million in total sales, Bio-Techne Corporation saw significant contributions from the biopharma end markets and notable advancements in their ExosomeDx and spatial biology divisions.

Another report by Baptista Research, titled “Bio-Techne Corporation: An Insight Into Its Market Position & Product Expansion in Diagnostics and Spatial Biology! – Major Drivers”, focused on the company’s first-quarter financial results for Fiscal Year 2025. With a 4% year-over-year organic revenue growth, Bio-Techne Corporation demonstrated solid performance driven by stability in its biopharma end markets and strong execution in areas like cell and gene therapy. The analysts at Baptista Research also conducted an independent valuation of the company using a Discounted Cash Flow (DCF) methodology to evaluate potential factors influencing its future price.

A look at Bio-Techne Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Bio Techne Corp appears to have a moderate outlook across various factors. With scores of 3 out of 5 for Value, Dividend, Growth, Resilience, and Momentum, the company seems to be performing steadily in these areas. This suggests that Bio Techne Corp may offer a balanced investment opportunity, with room for potential growth and stability.

Bio Techne Corp is a company that develops, manufactures, and sells biotechnology products and clinical diagnostic controls. Specializing in proteins, cytokines, growth factors, immunoassays, and small molecules, the company plays a key role in the biotechnology industry. With its moderate scores across different factors, Bio Techne Corp seems to be positioned for continued growth and resilience in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma